Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 7Neoplasms 5Carcinoma, Non-Small-Cell Lung 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Hepatocellular 2Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Melanoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1Anophthalmia with pulmonary hypoplasia 1

Interventions

budigalimab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anophthalmia with pulmonary hypoplasia × budigalimab × Head & Neck × Clear all
NCT05005403 2026-05-13

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

AbbVie

Phase 1 Recruiting
694 enrolled
BreastGastrointestinalHead & NeckThoracic

Anophthalmia with pulmonary hypoplasia, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡